Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
Liva, Sophia G, Tseng, Yu‐Chou, Dauki, Anees M, Sovic, Michael G, Vu, Trang, Henderson, Sally E, Kuo, Yi‐Chiu, Benedict, Jason A, Zhang, Xiaoli, Remaily, Bryan C, Kulp, Samuel K, Campbell, Moray, Bekaii‐Saab, Tanios, Phelps, Mitchell A, Chen, Ching‐Shih, Coss, Christopher C
Published in EMBO molecular medicine (07.02.2020)
Published in EMBO molecular medicine (07.02.2020)
Get full text
Journal Article
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study
Taylor, Peter C, Schett, Georg, Huizinga, Tom WJ, Wang, Qingmin, Ibrahim, Fowzia, Zhou, Bei, Liva, Sophia G, Shaik, Jafar Sadik B, Xiong, Yuan, Leu, Jocelyn H, Panchakshari, Rohit A, Loza, Matthew J, Ma, Keying, Dhatt, Harman, Rojo Cella, Ricardo, Karyekar, Chetan S, Cuff, Carolyn A, Gao, Sheng, Fei, Kaiyin
Published in Rheumatic & musculoskeletal diseases open (28.06.2024)
Published in Rheumatic & musculoskeletal diseases open (28.06.2024)
Get full text
Journal Article
Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans
Castillo, Alyssa Marie M., Vu, Trang T., Liva, Sophia G., Chen, Min, Xie, Zhiliang, Thomas, Justin, Remaily, Bryan, Guo, Yizhen, Subrayan, Uma L., Costa, Travis, Helms, Timothy H., Irby, Donald J., Kim, Kyeongmin, Owen, Dwight H., Kulp, Samuel K., Mace, Thomas A., Phelps, Mitch A., Coss, Christopher C.
Published in JCSM rapid communications (01.07.2021)
Published in JCSM rapid communications (01.07.2021)
Get full text
Journal Article
Development of Therapeutic Proteins for a New Subcutaneous Route of Administration After the Establishment of Intravenous Dosages: A Systematic Review
Xu, Zhenhua, Leu, Jocelyn H, Xu, Yan, Nnane, Ivo, Liva, Sophia G, Wang-Lin, Shun Xin, Kudgus-Lokken, Rachel, Vermeulen, An, Ouellet, Daniele
Published in Clinical pharmacology and therapeutics (01.05.2023)
Published in Clinical pharmacology and therapeutics (01.05.2023)
Get more information
Journal Article
A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies
Collier, Katharine A., Valencia, Hugo, Newton, Herbert, Hade, Erinn M., Sborov, Douglas W., Cavaliere, Robert, Poi, Ming, Phelps, Mitch A., Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Khountham, Soun, Monk, Paul, Shapiro, Charles L., Piekarz, Richard, Hofmeister, Craig C., Welling, D. Bradley, Mortazavi, Amir
Published in Cancer chemotherapy and pharmacology (01.05.2021)
Published in Cancer chemotherapy and pharmacology (01.05.2021)
Get full text
Journal Article
Phase I study of AR-42 and decitabine in acute myeloid leukemia
Liva, Sophia G., Coss, Christopher C., Wang, Jiang, Blum, William, Klisovic, Rebecca, Bhatnagar, Bhavana, Walsh, Katherine, Geyer, Susan, Zhao, Qiuhong, Garzon, Ramiro, Marcucci, Guido, Phelps, Mitch A., Walker, Alison R.
Published in Leukemia & lymphoma (11.05.2020)
Published in Leukemia & lymphoma (11.05.2020)
Get full text
Journal Article
Overcoming Resistance to Anabolic Selective Androgen Receptor Modulator (SARM) Therapy in Experimental Cancer Cachexia with Histone Deacetylase Inhibitor AR-42
Yu-Chou, Tseng, Liva, Sophia G, Dauki, Anees M, Sovic, Michael, Henderson, Sally E, Yi-Chiu, Kuo, Benedict, Jason A, Kulp, Samuel K, Campbell, Moray, Bekaii-Saab, Tanois, Phelps, Mitchell A, Ching-Shih, Chen, Coss, Christopher C
Published in bioRxiv (05.10.2018)
Published in bioRxiv (05.10.2018)
Get full text
Paper